TriangleLeukapheresis (NCT07316010)
Leukapheresis trial for Large B-cell Lymphoma (NCT07316010). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with specified higher-risk large B-cell lymphomas and detectable lymphoma DNA after six cycles of first-line chemoimmunotherapy. A complete metabolic response, or selected partial responses suitable for observation, is required; overt relapse is excluded.
The idea: lisocabtagene maraleucel uses the patient's T cells engineered to recognize CD19. After cell collection and intravenous lymphodepleting chemotherapy, patients receive the cell infusion. Researchers assess safety, residual-disease clearance, and whether recurrence is delayed.
This phase 2 study plans 50 patients. Dai Chihara leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.